BioPharmSignal logoBioPharmSignal

Biotech News

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics (GYRE)Gyre TherapeuticsCommercial

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of

Related news

GYREGyre Therapeutics2026-09-03 11:00 EST

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

VERAVera Therapeutics2026-09-01 11:30 EST

Vera Therapeutics to Participate at Upcoming Investor Conferences

GYREGyre Therapeutics2026-11-05 21:08 EST

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

IFRXInflarx NV2026-11-03 12:00 EST

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

XFORX4 Pharmaceuticals2026-10-08 11:00 EST

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

RNACCartesian Therapeutics2026-11-03 12:00 EST

Cartesian Therapeutics Announces New Employment Inducement Grant

ATRAAtara Biotherapeutics, Inc.2026-10-14 12:05 EST

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

RNACCartesian Therapeutics2026-10-02 11:00 EST

Cartesian Therapeutics Announces New Employment Inducement Grants

View all latest news

Gyre Therapeutics

Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China. Its small-molecule portfolio is centered on organ fibrosis and inflammatory diseases. Commercial Products in China Gyre Pharmaceuticals commercializes ETUARY, a pirfenidone therapy for idiopathic...

Recent company news

GYREGyre Therapeutics2026-11-05 21:08 EST

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

GYREGyre Therapeutics2026-09-03 11:00 EST

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

GYREGyre Therapeutics2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

GYREGyre Therapeutics2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Stock data

Close
4.01 USD
Market cap
539.48M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States